Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Single-Payer Healthcare
  • Federal Workers’ Medical Records
  • TrumpRx
  • Pharmacy Discount Coupons
  • Hantavirus

WHAT'S NEW

  • Single-Payer Healthcare
  • Federal Workers' Medical Records
  • TrumpRx
  • Pharmacy Discount Coupons
  • Hantavirus

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Apr 20 2023

Full Issue

Research Roundup: All About Covid

This week, KFF Health News spotlights health studies reported by the Center for Infectious Disease Research and Policy (CIDRAP).

CIDRAP: Two Drug Combos Show Protection Against Severe COVID-19 

Two new randomized, controlled trials published yesterday in the Annals of Internal Medicine describe how drug combinations lowered the risk of severe COVID-19, with one detailing use of the antidepressant fluvoxamine plus the corticosteroid budesonide, and the other outlining the monoclonal antibody duo amubarvimab plus romlusevimab. (Van Beusekom, 4/18)

CIDRAP: Early Steroid Use For Severe COVID-19 Tied To Fewer Deaths 

JAMA Network Open has published a new US national cohort study demonstrating that early administration of the steroid dexamethasone was associated with significantly reduced odds of mortality or discharge to hospice in those requiring supplemental oxygen or mechanical ventilation and/or extracorporeal membrane oxygenation. (Soucheray, 4/18)

CIDRAP: Study: COVID Disturbed Sleep Patterns, Leading To Breathlessness Post-Infection

New research published in The Lancet Respiratory Medicine and presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) suggests the altered sleep patterns in British residents hospitalized with COVID-19 likely contributed to developing breathlessness, or dyspnea following recovery from the initial illness. This is the first known study linking breathlessness and sleep disturbances, two common symptoms noted during and following COVID-19 infection. (Soucheray, 4/17)

CIDRAP: Study: Severely Ill COVID Patients At 16 Times Higher Risk For Abnormally Rapid Heartbeat 

COVID-19 patients requiring mechanical ventilation are 16 times more likely than non-severely ill peers to experience ventricular tachycardia, an abnormal heart rhythm, within 6 months, according to a study presented at this week's annual meeting of the European Heart Rhythm Association (EHRA) in Barcelona, Spain. Ventricular tachycardia is a potentially fatal arrhythmia that occurs when the heart's ventricle beats too fast to pump enough oxygenated blood to the rest of the body. (Van Beusekom, 4/19)

CIDRAP: COVID Death Rate 5 Times Higher In Dutch Adults With Learning Disabilities In 2020-21

Dutch adults with intellectual disabilities died of COVID-19 at a rate five times higher than the general population in the first 2 years of the pandemic, finds a study published yesterday in The Lancet Public Health. (Van Beusekom, 4/17)

CIDRAP: Preprint COVID-19 Studies Subject To More 'Spin' During Pandemic

Preprint, non–peer-reviewed studies rose in visibility dramatically during the COVID-19 pandemic, as scientists around the global tried to decipher and describe the novel coronavirus. An analysis yesterday in JAMA shows that preprint study abstracts were more incomplete and more prone to "spin"—or deceptive persuasion—in the preprint stage compared with published study that followed. (Soucheray, 4/19)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, May 11
  • Friday, May 8
  • Thursday, May 7
  • Wednesday, May 6
  • Tuesday, May 5
  • Monday, May 4
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF